Medtronic, Merck, Williams Companies And More: CNBC's 'Final Trades'
Portfolio Pulse from Priya Nigam
CNBC's 'Halftime Report Final Trades' featured recommendations from financial experts, including iShares 7-10 Year Treasury Bond ETF (IEF), Medtronic (MDT), Merck (MRK), and Williams Companies (WMB). Medtronic recently issued weak guidance and announced the acquisition of EOFlow, while Merck announced positive data from a Phase 3 trial for advanced renal cell carcinoma treatment. Williams Companies posted better-than-expected Q1 results.
June 01, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Joseph Terranova of Virtus Investment Partners recommended Merck (MRK) on CNBC's 'Halftime Report Final Trades'. Merck recently announced positive data from a Phase 3 trial for advanced renal cell carcinoma treatment.
The positive data from the Phase 3 trial could lead to increased investor confidence in Merck's potential for growth in the oncology market. This news is likely to have a positive short-term impact on MRK's stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 75
POSITIVE IMPACT
Jenny Harrington of Gilman Hill Asset Management recommended Williams Companies (WMB) on CNBC's 'Halftime Report Final Trades'. Williams Companies recently posted better-than-expected results for its first quarter.
The better-than-expected Q1 results indicate strong performance by Williams Companies, which could lead to increased investor confidence and a positive short-term impact on WMB's stock price.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 75
NEUTRAL IMPACT
Anastasia Amoroso of JPMorgan Private Bank recommended iShares 7-10 Year Treasury Bond ETF (IEF) on CNBC's 'Halftime Report Final Trades'.
As a recommendation from a JPMorgan analyst, IEF may see some increased interest from investors. However, the short-term impact on the ETF's price is uncertain, as it depends on various factors such as market conditions and investor sentiment.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
Jason Snipe of Odyssey Capital Advisors recommended Medtronic (MDT) on CNBC's 'Halftime Report Final Trades'. Medtronic recently issued weak guidance and announced the acquisition of EOFlow.
The acquisition of EOFlow may have a positive impact on Medtronic's long-term growth, but the weak guidance could offset any short-term gains. The overall short-term impact on MDT's stock price is uncertain.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 75